Observational Study to Evaluate Fluid Resolution and Effectiveness of Brolucizumab for nAMD in Portugal

Prior treatment

• Patients treated for RVO, DME, mCNV, and have diagnoses of diabetes-related macular degeneration within 6 months prior to the index date
• Patients that have any contraindication and are not eligible for treatment with brolucizumab as according to the SmPC
• Patients participating in parallel in any other NIS generating primary data for an anti-VEGF drug
• Retinal pigment epithelial rip/tear in the study eye at Screening or Baseline or current vitreous hemorrhage or history of vitreous hemorrhage in the study eye within 4 weeks prior to Baseline

Other illness

• Any active intraocular or periocular infection or active intraocular inflammation in either eye at index date
• Any medical or psychological condition in the treating physician's opinion which may prevent the patient from the 24 months study participation

Other

• Receipt of any anti-VEGF treatment other than brolucizumab in the study eye at index date
• Central subfield of the study eye affected by fibrosis or geographic atrophy or total area of fibrosis >50% of the total lesion in the study eye at Screening
• Patients who have been on anti-VEGF treatment for longer than 3 years (before index date)
• Patients participating in parallel in an interventional clinical trial
• Subretinal blood affecting the foveal center point and/or >50% of the lesion of the study eye at Screening

• Diagnosis of nAMD
• Male and Female patients with ≥40 years of age at index
• Receipt of at least one injection of brolucizumab during the recruitment period
• Signed written informed consent